User login
Supplement Editor:
Leonard Calabrese, DO
Contents
Introduction: Progressive multifocal leukoencephalopathy in the biologic era
Leonard Calabrese, DO
History and current concepts in the pathogenesis of PML
Eugene O. Major, PhD
The clinical features of PML
Joseph R. Berger, MD
Pharmacovigilance and PML in the oncology setting
Charles L. Bennett, MD, PhD, MPP
Multiple sclerosis, natalizumab, and PML: Helping patients decide
Richard R. Rudick, MD
HIV-associated PML: Changing epidemiology and clinical approach
David M. Simpson, MD, FRCP, MRCPI
PML and rheumatology: The contribution of disease and drugs
Eamonn S. Molloy, MD, MS, MRCPI
Advances in the management of PML: Focus on natalizumab
Robert Fox, MD
A rational approach to PML for the clinician
Leonard Calabrese, DO
Supplement Editor:
Leonard Calabrese, DO
Contents
Introduction: Progressive multifocal leukoencephalopathy in the biologic era
Leonard Calabrese, DO
History and current concepts in the pathogenesis of PML
Eugene O. Major, PhD
The clinical features of PML
Joseph R. Berger, MD
Pharmacovigilance and PML in the oncology setting
Charles L. Bennett, MD, PhD, MPP
Multiple sclerosis, natalizumab, and PML: Helping patients decide
Richard R. Rudick, MD
HIV-associated PML: Changing epidemiology and clinical approach
David M. Simpson, MD, FRCP, MRCPI
PML and rheumatology: The contribution of disease and drugs
Eamonn S. Molloy, MD, MS, MRCPI
Advances in the management of PML: Focus on natalizumab
Robert Fox, MD
A rational approach to PML for the clinician
Leonard Calabrese, DO
Supplement Editor:
Leonard Calabrese, DO
Contents
Introduction: Progressive multifocal leukoencephalopathy in the biologic era
Leonard Calabrese, DO
History and current concepts in the pathogenesis of PML
Eugene O. Major, PhD
The clinical features of PML
Joseph R. Berger, MD
Pharmacovigilance and PML in the oncology setting
Charles L. Bennett, MD, PhD, MPP
Multiple sclerosis, natalizumab, and PML: Helping patients decide
Richard R. Rudick, MD
HIV-associated PML: Changing epidemiology and clinical approach
David M. Simpson, MD, FRCP, MRCPI
PML and rheumatology: The contribution of disease and drugs
Eamonn S. Molloy, MD, MS, MRCPI
Advances in the management of PML: Focus on natalizumab
Robert Fox, MD
A rational approach to PML for the clinician
Leonard Calabrese, DO
